Last reviewed · How we verify

Pembrolizumab/Vibostolimab — Competitive Intelligence Brief

Pembrolizumab/Vibostolimab (Pembrolizumab/Vibostolimab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + VISTA inhibitor combination. Area: Oncology.

phase 3 PD-1 inhibitor + VISTA inhibitor combination PD-1 and VISTA Oncology Biologic Live · refreshed every 30 min

Target snapshot

Pembrolizumab/Vibostolimab (Pembrolizumab/Vibostolimab) — Merck Sharp & Dohme LLC. Pembrolizumab blocks PD-1 to enhance T-cell immunity, while vibostolimab blocks VISTA to further relieve immune suppression in the tumor microenvironment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pembrolizumab/Vibostolimab TARGET Pembrolizumab/Vibostolimab Merck Sharp & Dohme LLC phase 3 PD-1 inhibitor + VISTA inhibitor combination PD-1 and VISTA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + VISTA inhibitor combination class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pembrolizumab/Vibostolimab — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-vibostolimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: